ReviR Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
150 N Hill Dr, Brisbane, California, 940...Website
www.revirtx.comRevenue
$5.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
2
1
1
1
About ReviR Therapeutics
REVIR is a biotechnology company focused on improving human health through drug discovery built on RNA science and artificial intelligence. The company develops therapeutic programs and discovery capabilities intended to identify and advance new medicines for serious diseases with unmet medical need.Explore more
ReviR Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ReviR Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on ReviR Therapeutics recently announced quarterly report
Check out if ReviR Therapeutics is spiking on competitors!
Check if ReviR Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if ReviR Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once ReviR Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when ReviR Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at ReviR Therapeutics
ReviR Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined ReviR Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to ReviR Therapeutics
Compare insights from companies similar to ReviR Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ReviR Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ReviR Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ReviR Therapeutics.
ReviR Therapeutics financials insights
Gather financial insights about ReviR Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$20M
2024
Series A
$30M
ReviR Therapeutics Tech Stack
A closer look at the technologies used by ReviR Therapeutics
Most Recent Scoops
Funding
Funding
Person-Based
Project
Product Development, Research & Development, Intellectual Property, Legal Affairs, Safety, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Person-Based
Funding
Funding
ReviR Therapeutics News & Media
ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT
An isogenic iPSC and AI-enabled disease modeling platform spanning multiple genetically defined CMT subtypes will be established to support patient stratification, accelerate RTX-117 development, and create a shared foundation for next-generation therapies BRISBANE, Calif., April 21, 2026...XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117
RTX-117 is an investigational small molecule designed to modulate the Integrated Stress Response (ISR) pathway, with the goal of restoring protein translation homeostasis implicated in Charcot-Marie-Tooth disease (CMT) and Vanishing White Matter disease (VWM) ReviR has dosed the first...ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven RNA-modulating small molecules to treat...ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington's Disease Treatment and Announces Key Development Milestone
BRISBANE, Calif., Nov. 20, 2025 /PRNewswire/ -- ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today that it has been awarded a $4.6M grant from the California Institute for Regenerative Medicine (CIRM), and has recently reached a key program milestone, having identified a lead compound that meets key development criteria. This funding will further support the advancement of ReviR Therapeutics' HTT-PMS1 genetic medicine prog
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding ReviR Therapeutics
Sign Up For FreeTo access detailed company insights
REVIR is a biotechnology company focused on improving human health through drug discovery built on RNA science and artificial intelligence. The company develops therapeutic programs and discovery capabilities intended to identify and advance new medicines for serious diseases with unmet medical need.... Read More
